AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
cis-dominant mutation A mutation occurring within a cis-regulatory element (such as an operator) which alters the functioning of a nearby gene or genes on the same chromosome. Cis-dominant mutations affect the expression of genes because they occur at sites that control transcription rather than within the genes themselves.
This particular adaptation of the mixed economy, better known as the Nordic model, is characterised by more generous welfare states (relative to other developed countries) which are aimed specifically at enhancing individual autonomy, ensuring the universal provision of basic human rights and stabilising the economy. It is distinguished from other welfare states with similar goals by its emphasis on maximising labour force participation, promoting gender equality, egalitarian and extensive benefit levels, large magnitude of redistribution and expansionary fiscal policy. In the 1950s, popular socialism emerged as a vital current of the left in Nordic countries could be characterised as a democratic socialism in the same vein as it placed itself between communism and social democracy. In the 1960s, Gerhardsen established a planning agency and tried to establish a planned economy. Prominent Swedish Prime Minister Olof Palme identified himself as a democratic socialist. The Rehn–Meidner model was adopted by the Swedish Social Democratic Party in the late 1940s. This economic model allowed capitalists who owned very productive and efficient firms to retain excess profits at the expense of the firm's workers, exacerbating income inequality and causing workers in these firms to agitate for a better share of the profits in the 1970s. Women working in the state sector also began to assert pressure for better and equal wages.
Chief complaint (CC): the reason for the current medical visit. These are the symptoms. They are in the patient's own words and are recorded along with the duration of each one. Also called chief concern or presenting complaint. Current activity: occupation, hobbies, what the patient actually does professionally and non-professionally. Family history (FH): listing of diseases in the family that may impact the patient. A family tree is sometimes used. History of present illness (HPI): the chronological order of events of symptoms and further clarification of each symptom. Distinguishable from history of previous illness, often called past medical history (PMH). Medical history comprises HPI and PMH. Medications (Rx): what drugs the patient takes including prescribed, over-the-counter, and home remedies, as well as alternative and herbal medicines or remedies. Allergies are also recorded. Past medical history (PMH/PMHx): concurrent medical problems, past hospitalizations and operations, injuries, past infectious diseases or vaccinations, history of known allergies. Review of systems (ROS) or systems inquiry: a set of additional questions to ask, which may be missed on HPI: a general enquiry (have you noticed any weight loss, change in sleep quality, fevers, lumps and bumps? etc.), followed by questions on the body's main organ systems (heart, lungs, digestive tract, urinary tract, etc.). Social history (SH): birthplace, residences, marital history, social and economic status, habits (including diet, medications, tobacco, alcohol).
Sources: en.wikipedia.org
=== Freeze drying === Freeze drying is a special form of drying that removes all moisture and has less effect on the taste of food than normal dehydration. Freeze drying is a water removal process commonly used to preserve raw plant foods. The food is placed in a vacuum chamber at low heat to increase shelf life. This process works by freezing the material, then reducing the pressure and adding heat to neutralize the frozen water in the material. It may be spray-dried to produce a versatile powder for ingredient applications. Unlike the other drying methods, this method allows a dried plant food to retain its shape, retain the highest color value, and provide a rehydration property. Foods that contain adequate amounts of water are easy to work with and maintain their initial shape after the freeze-drying process is complete.
Guiry, Michael; Guiry, Wendy. "AlgaeBase". – a database of all algal names including images, nomenclature, taxonomy, distribution, bibliography, uses, extracts "Algae – Cell Centered Database". CCDb.UCSD.edu. San Diego: University of California. Anderson, Don; Keafer, Bruce; Kleindinst, Judy; Shaughnessy, Katie; Joyce, Katherine; Fino, Danielle; Shepherd, Adam (2007). "Harmful Algae". US National Office for Harmful Algal Blooms. Archived from the original on 5 December 2008. Retrieved 19 December 2008. "About Algae". NMH.ac.uk. Natural History Museum, United Kingdom.
Abrams, J.L. Embalming. 2008. Chisholm, Hugh, ed. (1911). "Embalming" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Frederick, L.G.; Strub, Clarence G. [1959] (1989). The Principles and Practice of Embalming, 5th ed., Dallas, TX: Professional Training Schools Inc & Robertine Frederick. OCLC 20723376. Mayer, Robert G. (2000). Embalming: History, Theory and Practice, 3rd ed., McGraw-Hill/Appleton & Lange. ISBN 978-0-8385-2187-8. Schmitz-Esser, Romedio (2013). "Embalming and Dissecting the Corpse between East and West: From ar-Razi to Henry de Mondeville". In Classen, Albrecht (ed.). East Meets West in the Middle Ages and Early Modern Times: Transcultural Experiences in the Premodern World. Fundamentals of Medieval and Early Modern Culture. Vol. 14. Berlin and Boston: De Gruyter. pp. 611–624. doi:10.1515/9783110321517.611. ISBN 9783110328783. ISSN 1864-3396. Besouchet, Lídia (1993). Pedro II e o Século XIX (in Portuguese) (2nd ed.). Rio de Janeiro: Nova Fronteira. ISBN 978-85-209-0494-7. Rezzutti, Paulo (2019). D. Pedro II: a história não contada: O último imperador do Novo Mundo revelado por cartas e documentos inéditos (in Portuguese). Leya. ISBN 978-85-7734-677-6. https://www.dignityfunerals.co.uk/what-to-do-when-someone-dies/what-is-embalming/
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.